Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Composition containing protein kinase inhibitor and resveratrol

A protein kinase inhibitor, resveratrol technology, applied in the field of medicine

Inactive Publication Date: 2018-12-25
黄泳华
View PDF1 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] In the prior art, there is no technical inspiration for the combination of protein kinase inhibitors and resveratrol to produce synergistic antibacterial effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition containing protein kinase inhibitor and resveratrol
  • Composition containing protein kinase inhibitor and resveratrol
  • Composition containing protein kinase inhibitor and resveratrol

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0060] Embodiment 1 comprises the preparation of the capsule of resveratrol and sunitinib malate (molar ratio is 0.01:1)

[0061] prescription

[0062]

[0063] Preparation

[0064] Take the prescribed amount of resveratrol, sunitinib malate, microcrystalline cellulose and sodium stearyl fumarate, mix thoroughly, fill capsules, and divide into packages.

Embodiment 2

[0065] Example 2 Preparation of tablets comprising resveratrol and lapatinib two-p-toluenesulfonate monohydrate (molar ratio of 0.5:1)

[0066] prescription

[0067]

[0068] Preparation

[0069] Take the prescribed amount of resveratrol, lapatinib di-p-toluenesulfonate monohydrate, microcrystalline cellulose, and sodium stearyl fumarate, mix thoroughly, and compress into tablets.

Embodiment 3

[0070] Example 3 Preparation of Granules Containing Resveratrol and Crizotinib (Molar Ratio of 1:1)

[0071] prescription

[0072]

[0073] Preparation

[0074] Take the prescribed amount of resveratrol, crizotinib, microcrystalline cellulose, and sodium stearyl fumarate, mix them thoroughly, and pack them separately.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention firstly provides a composition containing a protein kinase inhibitor and resveratrol. The composition is characterized in that the protein kinase inhibitor is one, or its pharmaceutically-acceptable salt or solvate or pharmaceutically-acceptable salt solvate, of sunitinib, lapatinib, pazopanib, afatinib, bosutinib, crizotinib, axitinib, and regorafenib; the molar ratio of resveratrolto the protein kinase inhibitor is (0.01-100):1. It is discovered through in-vitro antibacterial tests that the composition of the protein kinase inhibitor and resveratrol, in the molar ratio of (0.01-100):1, and can provide synergic antibacterial action against Kluyvera cryocrescens and other bacteria (interaction index CI<1 upon 30% of inhibition).

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to a composition containing protein kinase inhibitors and resveratrol. Background technique [0002] Infectious diseases are a large class of diseases caused by microbial infections such as bacteria, parasites, fungi, or viruses, and can be transmitted directly or indirectly between humans through various channels. Although a variety of anti-infective drugs, including antibiotics, antivirals, antifungals, and antiparasitics, are currently available for the treatment of infectious diseases, this disease remains one of the leading causes of illness or death worldwide. In 2010, approximately 15 million people worldwide died from infectious diseases. [0003] In 2001, the first protein kinase inhibitor imatinib was launched for the treatment of leukemia, which opened the prelude to the targeted therapy of tumors. As of October 2018, the FDA has approved more than ten prot...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K45/06A61K31/05A61P31/04A61P31/10
CPCA61K31/05A61K45/06A61P31/04A61P31/10A61K2300/00
Inventor 向飞孙伟光卢剑飞黄泳华
Owner 黄泳华
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com